Showing 8901-8910 of 18563 results for "".
- MEK Inhibition Shows Promise in Aggressive EB-Linked Skin Cancershttps://reachmd.com/news/mek-inhibition-shows-promise-in-aggressive-eb-linked-skin-cancers/2485197/A transcriptome-driven drug repurposing strategy has identified selumetinib as a potential therapeutic candidate for aggressive squamous cell carcinomas (SCCs) arising in recessive dystrophic epidermolysis bullosa (RDEB). Resea
- Emerging Threats: Genomic Insights and Clinical Implications of Carbapenem-Resistant K. pneumoniaehttps://reachmd.com/news/emerging-threats-genomic-insights-and-clinical-implications-of-carbapenem-resistant-k-pneumoniae/2485176/A genomic analysis of 99 carbapenem-resistant Klebsiella pneumoniae isolates documents a shifting clonal landscape: ST11 remains dominant (63.6%, 63/99), while an emergent
- Bioactive Chitosan–dECM Composite Shows Preclinical Promise for Inflammatory Hair Losshttps://reachmd.com/news/bioactive-chitosandecm-composite-shows-preclinical-promise-for-inflammatory-hair-loss/2485093/A novel topical composite combining amine-activated carboxymethyl chitosan (aaCMC) and hydrolyzed decellularized extracellular matrix (h-dECM) demonstrated antioxidant, immunomodulatory, and regenerative effects in preclinical models of inflammatory scalp injury, according to new research publish
- Revolutionizing Tuberculosis Treatment: Emerging Inhalable and Nanoformulation Delivery Systemshttps://reachmd.com/news/revolutionizing-tuberculosis-treatment-emerging-inhalable-and-nanoformulation-delivery-systems/2485180/Inhalable aerosols and nanoformulation platforms now promise improved lung deposition and reduced systemic toxicity for pulmonary tuberculosis therapies.
- Innovations in Pharmaceuticals: From HSP90 Inhibition to FAPI Theranosticshttps://reachmd.com/news/innovations-in-pharmaceuticals-from-hsp90-inhibition-to-fapi-theranostics/2485175/A new calenduloside E derivative shows cytoprotective activity in vascular endothelial cells, while recent advances in radiolabeled FAPI tracers strengthen options for tumor imaging and theranostics.
- Pediatric Respiratory Virus Burden: Recent Insights and Implications from Polandhttps://reachmd.com/news/pediatric-respiratory-virus-burden-recent-insights-and-implications-from-poland/2485156/A multicenter retrospective observational study from Poland’s 2022–23 RSV season found infants shouldered the clinical burden: 57.4% of hospitalized child
- New Insights into Early Eye-Tracking Biomarkers for Autism Spectrum Disorder Risk Assessmenthttps://reachmd.com/news/new-insights-into-early-eye-tracking-biomarkers-for-autism-spectrum-disorder-risk-assessment/2485150/A recent study shows that brief, dynamic social-attention paradigms and novel gaze-retention (GRI) metrics distinguish toddlers with higher versus lower ADOS-indicated risk—offering earlier, objec
- Impact of Surgical Approach on Postoperative Independence in Elderly Patients Undergoing Pancreatoduodenectomyhttps://reachmd.com/news/impact-of-surgical-approach-on-postoperative-independence-in-elderly-patients-undergoing-pancreatoduodenectomy/2485158/Minimally invasive pancreatoduodenectomy demonstrated a lower risk of postoperative loss of independence (LOI) in older adults than open surgery in a single-center cohort — a
- Innovative Dosimetric Advances in Total-Body PET/CT with PD-L1 Tracershttps://reachmd.com/news/innovative-dosimetric-advances-in-total-body-petct-with-pd-l1-tracers/2485157/A new hybrid curve-fitting method for total-body dynamic PET/CT raises estimated radiation doses for a PD-L1–targeted tracer and narrows uncertainty in time–activity integration for oncologic dosimetry. The study used total-body dynamic PET/CT in 16 patients with sol
- Antimicrobial Resistance in Vibrio cholerae: Insights from a 2023 Outbreakhttps://reachmd.com/news/antimicrobial-resistance-vibrio-cholerae/2485142/The 2023 Khyber Pakhtunkhwa cholera outbreak revealed extensive multidrug resistance that materially complicated clinical management and increased the risk of treatment failure. Investigators used